Same PBM Conduct Means Same Insulin Price Trial, FTC Says
By Bryan Koenig · November 7, 2024, 5:04 PM EST
Federal Trade Commission staffers want Caremark Rx, Express Scripts and OptumRx kept together in a single in-house case accusing the pharmacy benefit managers of artificially inflating insulin prices through unfair rebate...
To view the full article, register now.